Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab plus CyBorD vs CyBorD in AL amyloidosis (China sub-study of global phase 3)
CTR20182174Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of daratumumab in light-chain amyloidosis, sponsored by Janssen Pharmaceutical. Started Dec 2018; status: completed.
02
Drugs
daratumumab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on CTR20182174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182174.